Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04015375 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Torrent Pharmaceuticals Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
NCT04015375: Completed Phase 3 study, sponsored by Torrent Pharmaceuticals Limited.
NCT04015375 is a Phase 3 study that has completed, run by Torrent Pharmaceuticals Limited. The registered enrollment target is 1,150 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04015375, a Phase 3 study, has completed, sponsored by Torrent Pharmaceuticals Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
Study Summary
To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.
Primary Outcome
Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts
Interventions
- DRUG Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
- DRUG ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
- OTHER Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2020-02-22 |
| Phase | Phase 3 |
What the finished NCT04015375 record still lists
NCT04015375 is an interventional study that assigns participants to a tested intervention. Its 1,150 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% higher).
The record links to 0 conditions, and to 3 interventions - of which Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) is the first listed.
NCT04015375 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04015375 about?
NCT04015375 is a clinical study titled "Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris". To evaluate the therapeutic effect of Dapsone and Placebo gel in the treatment of acne vulgaris.
What is the current status of trial NCT04015375?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2019-07-11. Estimated completion is 2020-02-22.
What interventions are being tested in trial NCT04015375?
The interventions under investigation include: Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) (DRUG), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.) (DRUG), Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd) (OTHER).
Who is sponsoring clinical trial NCT04015375?
This trial is sponsored by Torrent Pharmaceuticals Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04015375's enrollment target sits among peer trials
1,150 238th of 2000 higher than 1,759 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
- NCT07339423 · 1,150 participants · Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI